---
schema_version: "secwatch.filing_event.v1"
accession: "0000882095-25-000003"
form_type: "8-K"
ticker: "GILD"
cik: "0000882095"
company_name: "GILEAD SCIENCES, INC."
filed_at: "2025-02-11T23:59:59+00:00"
generated_at: "2026-05-26T23:41:19.124690+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Gilead Q4 revenue up 6% to $7.6B; full year EPS hit by $4.2B impairment

## Summary
- Q4 product sales ex-Veklury +13% to $7.2B; HIV sales +16% to $5.5B, Biktarvy +21% to $3.8B.
- Full year 2024 diluted EPS $0.38 vs $4.50, reflecting $4.2B Immunomedics IPR&D impairment and $3.9B CymaBay charge.
- Non-GAAP diluted EPS Q4 $1.90 (+10%); full year $4.62 vs $6.72; cash, equivalents & securities $10.0B.
- FY2025 guidance: product sales $28.2-28.6B; non-GAAP EPS $7.70-8.10; Veklury sales expected $1.4B.
- Issued $3.5B senior notes in Q4; paid $973M dividends and repurchased $350M stock.

## SEC filing metadata
- accession: 0000882095-25-000003
- form_type: 8-K
- ticker: GILD
- cik: 0000882095
- company_name: GILEAD SCIENCES, INC.
- filed_at: 2025-02-11T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/882095/000088209525000003/0000882095-25-000003-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/882095/000088209525000003/gild-20250211.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000882095-25-000003
- JSON: https://secwatch.observer/filing/0000882095-25-000003.json
- Plain text: https://secwatch.observer/filing/0000882095-25-000003.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.